Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411818 | SCV000485533 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2015-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001384946 | SCV001584647 | pathogenic | Spastic paraplegia | 2020-04-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in SACS are known to be pathogenic (PMID: 18465152, 20876471). This variant has been observed in individual(s) with SACS-related conditions (PMID: 22816526). ClinVar contains an entry for this variant (Variation ID: 370271). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Leu410Serfs*2) in the SACS gene. It is expected to result in an absent or disrupted protein product. |
Genome- |
RCV000411818 | SCV002027668 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411818 | SCV004209987 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-05-08 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000411818 | SCV002086741 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-05-20 | no assertion criteria provided | clinical testing |